FDA Ban on GLP-1 Compounds for Weight-Loss Goes into Full Effect

A stethoscope on top of a medical chart.
Photo by Curated Lifestyle on Unsplash. Unsplash+ license obtained by editor.
Published: 21 May, 2025
Updated: 18 Jun, 2025
2 min read

WASHINGTON, D.C. - A new federal enforcement deadline is set to reshape access to some of the country’s most in-demand weight-loss drugs. Starting May 22, the U.S. Food and Drug Administration (FDA) will prohibit most pharmacies and providers from producing or distributing compounded versions of GLP-1 medications semaglutide and tirzepatide, active ingredients in blockbuster drugs including Ozempic, Wegovy, Mounjaro, and Zepbound.

The move follows months of mounting pressure on regulators to tighten control over the rapidly expanding market for GLP-1-based therapies used for diabetes management and weight loss. 

Demand has soared in recent years, creating temporary shortages that allowed compounding pharmacies to fill the gap with cheaper, unbranded alternatives. During the shortage period, the FDA tolerated compounding GLP-1 drugs as a temporary workaround. 

However, Novo Nordisk and Eli Lilly informed the FDA that the supply had improved. In February, the FDA determined that the supply from both companies had indeed stabilized, ending the emergency provision. 

Most compounded versions of the drugs will no longer be allowed unless they are made for a specific individual with a valid prescription and a medical need that cannot be met with a commercially available product.

Under federal law, drug compounding is allowed in limited cases when medications must be tailored to meet a patient’s unique clinical needs, such as when a patient is allergic to an ingredient in the brand-name version. However, producing compounded drugs in bulk or for general use, especially when FDA-approved versions are available in sufficient supply, is not permitted.

Novo Nordisk is the sole manufacturer of FDA-approved medications containing semaglutide. Its products, Ozempic and Wegovy, have become household names. Eli Lilly manufactures FDA-approved tirzepatide-based drugs such as Mounjaro and Zepbound, which have similarly gained traction.

Some compounders challenged the change, filing legal motions, but the federal courts have ruled against them, clearing the way for full enforcement of the ban on copycats, starting May 22.

FDA Revises COVID-19 Vaccine Policy, Limiting Access for Healthy Individuals Under 65

In a significant policy shift, the FDA announced on May 20 that updated COVID-19 vaccines will now be primarily recommended for adults aged 65 and older and individuals aged six months and older with at least one high-risk health condition. 

IVP Donate

This marks a departure from the previous federal policy, which recommended annual COVID-19 shots for all Americans aged six months and older. Under the new guidelines, vaccine manufacturers must conduct randomized, controlled trials with robust outcome data before the FDA approves boosters for healthy individuals under 65.

On May 20, FDA Commissioner Marty Makary and U.S. vaccine regulator Vinay Prasad wrote in the New England Journal of Medicine that the benefit of repeated annual shots for healthy adults was uncertain.

Related articles

Elderly woman sitting in wheelchair staring out window.
Three Reps Put Party Labels Aside to Strengthen U.S. Role in Global Fight Against Alzheimer’s
Two California members of Congress, Ami Bera, M.D. (D-CA-06) and Young Kim (R-CA-40), introduced a bill Wednesday with Republican Pennsylvania Rep. Brian Fitzpatrick aimed at bolstering the US's global role in the battle against Alzheimer’s disease. ...
04 Jun, 2025
-
3 min read
Presidential podium set up in White House.
Presidential Health: Who Determines When a President Is Unfit to Serve?
In this episode, Dan and Shawn examine how the system let this happen, how similar failures have played out in American history, and what it says about a two-party structure that forces voters to choose between different flavors of dysfunction, rather than ensuring effective governance....
20 May, 2025
-
1 min read
Man in suit sitting at desk writing on a document with a stethoscope on the desk and a map of California in the background.
AB 955 Revisited: How to Expand Cross-Border Care Without Sacrificing Patient Protections
IVN recently examined AB 955, by Assemblymember David Alvarez. The bill seeks to expand a healthcare service program I created in 1998 as the author of SB1658....
14 May, 2025
-
4 min read

Latest articles

homelessness in California
Clearing Homeless Encampments Is a Band-Aid, Not A Solution
Last July, Governor Gavin Newsom issued an executive order “to address (homeless) encampments” and allocated funding to local governments to clear encampments and connect “those living in them to housing and supportive services.” ...
20 Jun, 2025
-
3 min read
Thomas Massie
Thomas Massie and AOC: The Political Alliance No One Saw Coming in 2025
All eyes are on President Donald Trump to see if the US will further insert itself into the escalating military conflict between Israel and Iran. As the two nations continue to attack each other, the debate over US involvement is creating a rift between defense hawks and non-interventionists in the Republican Party....
20 Jun, 2025
-
5 min read
Bottle with a cannabis plant on it.
Is Texas About to Be More Chill on Hemp Than California?
California has just proposed a sweeping new rule to permanently ban intoxicating hemp products — and Texas may soon follow, as Governor Greg Abbott (R) faces a June 22 deadline to sign or veto a similar bill....
19 Jun, 2025
-
4 min read